Royce, M. Et Al. 2018. Everolimus Plus Endocrine Therapy for Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer A Clinical Trial. JAMA ONCOLOGY , vol.4, no.7 , 977-984.

Royce, M., BACHELOT, T., VILLANUEVA, C., Ozguroglu, M., AZEVEDO, S. J., CRUZ, F. M., ... DEBLED, M.(2018). Everolimus Plus Endocrine Therapy for Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer A Clinical Trial. JAMA ONCOLOGY , vol.4, no.7, 977-984.

Royce, Melanie Et Al. "Everolimus Plus Endocrine Therapy for Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer A Clinical Trial," JAMA ONCOLOGY , vol.4, no.7, 977-984, 2018

Royce, Melanie Et Al. "Everolimus Plus Endocrine Therapy for Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer A Clinical Trial." JAMA ONCOLOGY , vol.4, no.7, pp.977-984, 2018

Royce, M. Et Al. (2018) . "Everolimus Plus Endocrine Therapy for Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer A Clinical Trial." JAMA ONCOLOGY , vol.4, no.7, pp.977-984.

@article{article, author={Melanie Royce Et Al. }, title={Everolimus Plus Endocrine Therapy for Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer A Clinical Trial}, journal={JAMA ONCOLOGY}, year=2018, pages={977-984} }